DaVita DVA NYSE · Healthcare · United States
$174.49 +0.24% +$0.42
Summary
67 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 20% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $1.79B in the last fiscal year, 16% of its market value.
What to watch
- Repaying its net debt would take 4.6 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.9 USD for 1 USD of yearly profit. Over the last five years it was 13.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.4% a year over 5 years. Over the last 3 years it grew by 5.5% a year. For the next fiscal year analysts expect revenue to grow by 4.0%. Earnings per share grew by 20% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Sales and administration 16 USD
- Taxes and other 8.4 USD
- Net profit 6.5 USD
Net profit, industry median (Medical - Care Facilities) 7.3 USD
Out of every 100 USD of revenue, 6.5 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 10.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 10
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $238.5 is 37% above today's price. 43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- U S Dialysis And Related Lab Services 100%
By region
The company reports no revenue by region.
U S Dialysis And Related Lab Services brings in 100% of revenue.
Segments in detail